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Adeno-associated virus type 2 (AAV) is the only known eucaryotic virus capable of targeted integration in
human cells. AAV integrates preferentially into human chromosome (ch) 19q13.3qter. The nonstructural
proteins of AAV-2, Rep78 and Rep68, are essential for targeted integration. Rep78 and Rep68 are multifunc-
tional proteins with diverse biochemical activities, including site-specific binding to AAV and ch-19 target
sequences, helicase activity, and strand-specific, site-specific endonuclease activities. Both a Rep DNA binding
element (RBE) and a nicking site essential for AAV replication present within the viral terminal repeats are
also located on ch-19. Recently, identical RBE sequences have been identified at other locations in the human
genome. This fact raises numerous questions concerning AAV targeted integration; specifically, how many RBE
sequences are in the human genome? How does Rep discriminate between these and the ch-19 RBE sequence?
Does Rep interact with all sites and, if so, how is targeted integration within a fixed time frame facilitated? To
better characterize the role of Rep in targeted integration, we established a Rep-dependent filter DNA binding
assay using a highly purified Rep-68 fusion protein. Electron microscopy (EM) analysis was also performed to
determine the characteristics of the Rep-RBE interaction. Our results determined that the Rep affinity for
ch-19 is not distinct compared to other RBEs in the human genome when utilizing naked DNA. In fact, a
minimum-binding site (GAGYGAGC) efficiently associated with Rep, suggesting that as many as 2 3 105 sites
may exist. In addition, such sites also exist frequently in nonprimate mammalian genomes, although AAV
integrates site specifically into primate genomes. EM analysis demonstrated that only one Rep-DNA complex
was formed on ch-19 target DNA. Surprisingly, identically sized complexes were observed on all substrates
containing a RBE sequence, but never on DNA lacking an RBE. Rep-DNA complexes involved a multimeric
protein structure that spanned ca. 60 bp. Immunoprecipitation of AAV latently infected cells determined that
1,000 to 4,000 copies of Rep78 and Rep68 protein are expressed per cell. Comparison of the Rep association
constant with those of established DNA binding proteins indicates that sufficient molecules of Rep are present
to interact with all potential RBE sites. Moreover, Rep expression in the absence of AAV cis-acting substrate
resulted in Rep-dependent amplification and rearrangement of the target sequence in ch-19. This result
suggests that this locus is a hot spot for Rep-dependent recombination. Finally, we engineered mice to carry
a single 2.7-kb human ch-19 insertion containing the AAV ch-19 target locus. Using cells derived from these
mice, we demonstrated that this sequence was sufficient for site-specific recombination after infection with
transducing vectors expressing Rep. This result indicates that any host factors required for targeting are
conserved between human and mouse. Furthermore, the human ch-19 cis sequences and chromatin structure
required for site-specific recombination are contained within this fragment. Overall, these results indicate that
the specificity of targeted recombination to human ch-19 is not dictated by differential Rep affinities for RBE
sites. Instead, specificity is likely dictated by human ch-19 sequences that serve as a Rep protein-mediated
origin of replication, thus facilitating viral targeting through Rep-Rep interactions and host enzymes, resulting
in site-specific recombination. Control of specificity is clearly dictated by the ch-19 sequences, since transfer
of these sequences into the mouse genome are sufficient to achieve Rep-dependent site-specific integration.
Adeno-associated virus type 2 (AAV) contains a single-
stranded DNA genome of approximately 4.7 kb (50) and is a
member of the Parvoviridae family (3). AAV is unique among
other eucaryotic DNA viruses in that it utilizes a biphasic
lifecycle to persist in nature. In the presence of a helper virus,
adenovirus (Ad) or herpesvirus, AAV will undergo a produc-
tive infection. In the absence of a helper virus, AAV will
integrate preferentially (.70%) into chromosome (ch)
19q13.3qter (3, 35). The ability of this nonpathogenic DNA
virus, or virus-derived vector systems, to integrate site specif-
ically have made it an attractive candidate vector for human
gene therapy (45).
The AAV genome consists of two open reading frames
(ORFs), which comprise the rep and cap genes, and 145-bp
inverted terminal repeats (ITRs), which serve as the origins of
replication (3, 35). The left ORF of AAV encodes four non-
structural proteins, Rep78, Rep68, Rep52, and Rep40. Exten-
sive characterization of Rep78 and Rep68 in vitro has identi-
fied the following biochemical activities, DNA binding (18, 19),
site-specific and strand-specific endonuclease activities (17,
19), and DNA-RNA and DNA-DNA helicase activities (17, 19,
59), all of which appear to be necessary for viral replication
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(15, 53). More importantly, Rep78 and Rep68 are required for
mediating targeted integration (2, 43, 47, 51, 60).
Though site-specific integration is dependent upon either of
the two large Rep proteins, the AAV ITRs are the only cis
elements required for integration (34, 44, 61). In the absence
of Rep proteins, the virus will still integrate through the ITR
sequence but randomly into the host genome (21, 56, 61).
Although integration in the absence of the Rep proteins is
random, virus-cell junctions are nearly identical to junctions
formed during targeted integration (DNA microhomology at
junctions, specific deletions of the ITR sequences, rearrange-
ment of the chromosome locus, and head-to-tail virus concate-
mers) (41, 62). In fact, in vitro integration products generated
using cellular extracts produced identical type junctions, dem-
onstrating the essential role the ITRs play in viral integration
(62). From this analysis, Yang et al. (62) concluded that both
random and targeted integration are dependent upon a cellu-
lar recombination pathway, with the role of Rep facilitating
integration at ch-19. To help account for AAV targeting, a
nearly identical Rep binding element (RBE) and a nicking site
(trs) to that present on the AAV ITR was identified on the
ch19.13.3qter AAV integration sequence (23–25, 43, 46, 54,
57). It was also demonstrated that Rep68 could mediate com-
plex formation between the AAV ITR and the ch-19 integra-
tion site in vitro (57). This led to a hypothesis that AAV may
target integration by Rep-mediated complex formation be-
tween the AAV ITR and the ch19 integration site. However,
since this observation subsequent data has demonstrated that
Rep can bind to degenerate RBE sequences, (5, 32). In fact,
computer analysis identified at least 15 genomic genes which
contained RBE sites that bound to AAV Rep protein in vitro,
all more efficient than the ch-19 sequence (58). These data
raise the question as to how Rep can target ch-19 among other
RBE sequences. Using an Epstein-Barr virus (EBV)-based
shuttle vector system carrying sequences from ch-19, Linden et
al. demonstrated that the trs site was also critical for AAV
site-specific integration (29, 30). When the trs site was not
present, targeting was lost, even though the RBE was present.
The present study suggested that both sequences were essen-
tial for site-specific integration (the RBE and the trs sequenc-
es). The probability of identifying a RBE with the correct
proximity of a trs site would suggest a frequency of ,6 3
10211/genome, thereby defining a unique sequence in the hu-
man genome (54). While these studies identify ch-19 cis ele-
ments required for AAV targeted integration and suggest why
this reaction is specific, how Rep carries out this reaction
remains unclear.
Critical to any model of AAV Rep-mediated targeted inte-
gration is the ability to recognize the ch-19 target sequence
among other potential RBE sequences. Though Rep can bind
many degenerate sequences, the actual definition of what con-
stitutes an RBE is somewhat unclear. Random oligonucleotide
selection demonstrated that the RBE could be defined as an
8-bp sequence: 59-GAGYGAGC-39 (5). However, it was
shown by methylation interference assays that the RBE was an
18-bp core sequence and that any mutation within this se-
quence would significantly affect Rep binding (42). Also, the
report by Wonderling and Owens (58) demonstrated that the
RBE oligonucleotides derived from the BLAST search con-
tained mutations in this 18-bp core sequence but still bound
better to the MBP-Rep68 than to the ch-19 RBE. Depending
on the definition of an AAV RBE, the copy number present in
the human genome (GAGYGAGC 5 200,000 copies/genome,
whereas 18-bp core 5 1 copy/genome) could significantly im-
pact the ability of Rep to identify its target locus.
Based on the above information, the number of RBE se-
quences in the human genome, how Rep discriminates be-
tween these and the ch-19 target locus RBE sequence, and how
Rep interacts with all sites and still facilitates targeted integra-
tion within a fixed time frame become of significant impor-
tance. In this study, we evaluated the role of alternative RBEs
in the human genome and how these sequences might impact
the ability of Rep to target the locus on ch-19. Using a filter-
binding assay and a highly purified source of Rep68 protein, we
established that genomic DNA will compete efficiently against
a ch-19 target sequences. In this assay, a minimum Rep binding
site of 8-bp in the context of large DNA fragments demon-
strated competition, suggesting that as many as 200,000 poten-
tial binding sites may exist in the human genome. Filter-bind-
ing analysis of genomic DNA successfully retained ch-19 target
sequences, as well as a cellular RBE identified by BLAST
analysis, corroborating the competition results. Electron mi-
croscopy (EM) analysis was utilized to distinguish possible
differences between Rep protein DNA interaction with ch-19
RBE compared to a minimum 8-bp RBE sequence. Identical
multimeric Rep protein DNA complexes, which spanned about
60 bp, assembled on ch-19 target DNA, as well as a minimum
RBE site, but never on heterologous DNA lacking these se-
quences. At a high Rep concentration, protein DNA looping
structures were detected, but no evidence for paranemic struc-
tures were observed. In vivo analysis of Rep protein levels in a
latent infection demonstrated approximately 1 to 4,000 copies/
cell. Analysis of Rep expression in non-virus-infected cells
demonstrated DNA rearrangement of the ch-19 target se-
quence, suggesting that this locus is a hot spot for Rep-induced
DNA amplification and rearrangement that most likely influ-
ences AAV targeted integration. Finally, generation of an an-
imal model carrying the human ch-19 sequence at the mouse
hypoxanthine phosphoribosyltransferase (HPRT) locus facili-
tated AAV Rep-mediated targeted integration and corrobo-
rates the importance of the ch-19 RBE-trs sequence.
MATERIALS AND METHODS
Plasmids. The pRE2 plasmid contains the 2.66-kb BamHI subcloned fragment
from chromosome 19 (63). pAB11 plasmid (10) contains the 3.1-kb lacZ gene.
The pcCSF17 plasmid (ATCC 53149) contains the cDNA of CSF1. The pT7-7BT
plasmid is a derivative of the pT7-7 vector (1) but has the degenerate RBE
removed from its plasmid origin. SSV9 int2 was constructed by replacing the
XbaI fragment, which contained the AAV rep and cap genes with the XbaI
fragment from plasmid dl-int2 (a gift from N. Muzyczka). In this mutant, the
intron sequence has been specifically deleted. Thus, only Rep68 and Rep40 are
expressed (60). Plasmids were digested with the appropriate enzymes to generate
substrates and probes.
Escherichia coli expression vectors. The AAV Rep68 coding sequences were
cloned into the pQe70 vector (Qiagen). The AAV Rep68 ORF was PCR am-
plified from SSV9 int2 using Vent polymerase (New England Biolabs). Oligo-
nucleotides were 59-ACCATGCATGCCGGGGTTTTACGAG-39, which hy-
bridizes to nucleotides 320 through 337 of SSV9 int2, and 59-ACCATAGATC
TGAGAGAGTGTCCTCGAGC-39, which hybridizes to nucleotides 1910
through 1927 of SSV9 int2. The PCR product was digested with SphI and BglII
(NEB) and cloned into the pQe70 vector to generate a Rep68 histidine-tagged
fusion protein, which introduced eight new amino acids (RSHHHHHH) at the
carboxy end. This plasmid, pStump68, uses the original ATG of Rep68 and
places the Rep68H6 expression under IPTG (isopropyl-b-D-thiogalactopyrano-
side)-inducible control. pStump68 (Fig. 1) was transfected into SG13009 (13) (a
gift of S. Gottesman), which contained the pRep4 plasmid (Qiagen). pStump68
was also sequenced and was determined to contain a mutation that resulted in an
S536A mutation (University of North Carolina [UNC] sequencing facility). Ex-
pression of full-length fusion protein was confirmed by immunoblotting with
Rep-specific monoclonal antibodies (16).
Rep-specific antibodies. The IF11 antibody that recognizes all four Rep pro-
teins has been previously described (16). The Rep polyclonal antibody was
generated by immunizing a rabbit three times with 150 mg of the Rep68H6
protein each time (Spring Valley Laboratories).
Preparation of E. coli extracts. One liter of Stump68 cells, SG13009 cells that
contain the pRep4 and pStump68 plasmids, were grown at 37°C to an optical
density of 0.8 and were induced for 1 h with 0.1 mM IPTG. Cells were washed
in 50 mM NaPO4 (pH 8.1)–1 M NaCl and pelleted again. Cells were then
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resuspended in 50 mM NaPO4–1 M NaCl–0.1% Tween 20–10 mM b-mercapto-
ethanol (BME)–50 mM imidazole (pH 7.0)–0.5 mg of leupeptin per ml–0.7 mg of
pepstatin A per ml–0.1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were
then subjected to two freeze-thaws and incubated on ice in the presence of 1 mg
of lysozyme per ml for 30 min. They were then sonicated for 30 s on ice at an
output of 6 and a duty cycle of 50 on a Branson Sonifier 250 (VWR Scientific).
The lysate was centrifuged at 25,000 rpm in a Beckman SW41 centrifuge at 4°C
for 30 min. Glycerol was added to a final concentration of 20% to the soluble cell
lysate, which was then frozen at 280°C or used immediately.
Purification of Rep68. The soluble E. coli extract was applied to an Ni21-
nitriloacetic acid (NTA) (Qiagen) column (bed volume, 2 ml; diameter, 1.0 cm).
The column was equilibrated in 50 mM NaPO4–1 M NaCl–0.1% Tween 20–10
mM BME–50 mM imidazole (pH 7.0)–20% glycerol (equilibration buffer) or, in
later experiments, the buffer had a final pH of 8.1. The E. coli extract was then
applied to the column at a flow rate of 0.20 ml/min. The column was washed with
5 column volumes of mixture containing 50 mM NaPO4, 1 M NaCl, 0.1% Tween
20, 10 mM BME, 100 mM imidazole (pH 7.0), 20% glycerol, 0.5 mg of leupeptin
per ml, 0.7 mg of pepstatin A per ml, and 0.1 mM PMSF; the buffer was then
adjusted to a final pH of 6.0 (wash buffer) at flow rate of 0.5 ml/min. The protein
was eluted at a flow rate of 0.5 ml/min in an ascending linear gradient of 0.1 to
1 M imidazole in the wash buffer, except that the final pH was adjusted to 8.1.
The Ni-NTA fractions, which contained Rep68H6, were identified by silver
staining (Bio-Rad Silver Stain Plus). For some experiments the Rep68H6 frac-
tions were then pooled, dialyzed into 25 mM Tris-HCl (pH 7.5)–50 mM NaCl–10
mM BME–20% glycerol–0.5 mg of leupeptin per ml–0.7 mg of pepstatin A per
ml–0.1 mM PMSF, frozen at 280°C and designated Rep68H6 Nickel.
Rep68H6 Nickel fractions were dialyzed into 25 mM Tris-HCl (pH 8.0)–100
mM NaCl–0.1% Tween 20–0.1 mM EDTA–10 mM BME–20% glycerol (final
pH, 8.1) at 4°C (MonoQ equilibration buffer). The equilibrated Rep68 was then
applied to a 1-ml MonoQ fast-protein liquid chromatography (FPLC) column
(Pharmacia). The dialyzed Rep68H6 was applied to the MonoQ column at a flow
rate of 0.5 ml/min. The column was washed with 5 column volumes of MonoQ
equilibration buffer at flow rate of 1.0 ml/min. The protein was eluted in a linear
gradient ascending from 0.1 to 1.0 M NaCl in MonoQ equilibration buffer. The
contents of the peak were determined by silver staining (Bio-Rad Silver Stain
Plus). The Rep68H6 peak was pooled and dialyzed into 25 mM Tris-HCl (pH
8.0)–400 mM NaCl–1 mM dithiothreitol–0.1% Tween 20–20% glycerol and
stored at 280°C; this fraction was called Rep68H6. Both Rep68H6 Nickel and
Rep68H6 were shown to possess wild-type activities as determined by DNA
binding and trs endonuclease and DNA helicase assays (17). To determine Rep
protein concentrations the bicinchoninic acid assay was employed (Pierce, Inc.).
Filter-binding assays. Filter-binding assays were performed as described by
Fuller and his colleagues (11), with some modifications. The standard reaction
conditions contained 20 pmol of Rep68H6 incubated in a 300-ml reaction volume
which contained 10 mg of BamHI-digested HeLa genomic DNA and 10 mM
HEPES-NaOH (pH 7.8)–200 mM KCl–10% glycerol–10 mM BME. The reac-
tions were filtered under gentle suction (0.4 ml/min) on presoaked filters (Mil-
lipore Type HA, 0.45 mm [pore size]). Filters were washed with 10 ml of non-
elution buffer (25 mM Tris-HCl, pH 8.0; 200 mM KCl; 10% glycerol) under
gentle suction. The bound DNA was then eluted as previously described (8).
Exceptions to these conditions are noted. The eluted DNA was then analyzed on
agarose gels. In some experiments, various amounts of poly(dI-dC) (Pharmacia)
or digested HeLa genomic DNA was added to the reaction. In other experi-
ments, the concentration of KCl was varied. In some experiments various
amounts of 32P-end-labeled pRE2 fragment were included, while in other ex-
periments the volume of wash buffer was varied. Finally, competition assays were
performed using the 3.1-kb lacZ gene and the 2.7-kb ch-19 integration region,
and the 938-bp colony-stimulating factor (CSF) cDNA were purified away from
the plasmid backbone by digestion with appropriate restriction enzymes and
isolated by gel purification using the Gene Clean Kit (Bio 101).
Southern hybridization analysis. Filter-binding assays, which were carried out
with no labeled fragment, were electrophoresed in a 1.0% agarose gel along with
10 mg of HeLa genomic DNA, which was not subjected to the filter-binding
assays. Retained DNA was transferred to Gene Screen Plus (New England
Nuclear) as recommended by the manufacturer and hybridized at 65°C with
randomly labeled probes (Boehringer Mannheim) specific to the ch-19 integra-
tion region, the neomycin resistance gene, or exon one of CSF1 (20, 26). In some
other experiments mouse genomic DNA, which contained the human preinte-
gration region from ch-19 and were infected with AAV-Neo, was digested with
XbaI instead of BamHI. The digested mouse genomic DNA was analyzed for
integration by probing the blots with sequence-specific probes for ch-19 and the
neomycin gene. Site-specific integration was defined as cohybridization of the
two probes to the same band. Amplification of the ch-19 sequences in the
presence of Rep was determined by image quantification of bands compared to
control (non-Rep) lanes. Any lane in which the sum of the intensity of the signals
surpassed the intensity of the control lane was identified as amplified.
Preparation of protein-DNA complexes for EM. EM analysis was carried out
at the UNC EM Core Facility. Binding reactions were carried out as previously
described, except that reactions were 50 ml and included the BamHI-ScaI-
digested pRE2 plasmid at a concentration of 1 mg/ml and AAV no-end DNA
substrates (49). The BamHI-ScaI digestion released three fragments. The
2.66-kb ch-19 integration fragment, a 1.7-kb fragment which contains an RBE of
59-GAGTGAGC-39, and a 953-bp nonspecific fragment. Rep protein was added
to the reaction at a concentration of 25 monomers to 1 RBE.
Cross-linking of protein-DNA complexes was carried out by addition of glu-
taraldehyde to 0.6% and allowing the reaction mixture to incubate for 5 min at
room temperature. After 5 min reactions were applied to Bio-Gel A-5m (Bio-
Rad) columns, which had been equilibrated with 10 mM Tris-HCl (pH 7.6)–0.1
mM EDTA. The filtered samples were then incubated with a buffer containing 2
FIG. 1. Filter-binding assay. (A) Diagram of the modification to the AAV
Rep68 protein in the expression plasmid pStump68. pStump68 is a fusion con-
struct carrying a His tag (six amino acids) placed at the C terminus. The relevant
restriction sites (SphI and BglII), 59 and 39 DNA sequence, and amino acids
(letters below the DNA sequence) utilized in the cloning approach are illus-
trated. See Materials and Methods for details concerning the construction. (B)
Silver staining and Western blot analysis of purified Rep68H6. The left part of
panel B is a silver stain of 250 ng of purified Rep68H6. By silver stain analysis,
Rep68H6 was purified to apparent homogeneity. The right panel is a Western
blot showing that the band that appears on the silver stain is Rep specific. More
details concerning the purification can be found in the Materials and Methods.
(C) Rep filter-binding assay for RBE containing genomic fragments. Essentially,
purified Rep68H6 is incubated with digested HeLa genomic DNA (details are in
Materials and Methods), and the protein-DNA reaction is then passed over a
nitrocellulose filter and washed with a nonelution buffer. Rep-specific bound
DNA is eluted and fractionated on agarose gel and then analyzed by Southern
blotting.
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mM spermidine, 2 mM MgCl2, 0.15 M NaCl, and 0.10 M KCl (28) and adsorbed
to glow-charged thin carbon foils, dehydrated through a water-ethanol series and
rotary shadow cast with tungsten as described elsewhere (14). Samples were
visualized in a Philips CM12 instrument. Micrographs for publication were
scanned from negatives by using a Nikon multiformat film scanner; the contrast
was optimized and the panels were arranged using Adobe PhotoShop.
The 2.66-kb ch-19 integration contains an RBE located directly in the center
of the fragment; the 1.7-kb fragment contains an RBE located 180 nucleotides
from one end of the fragment, while the 953-bp fragment does not contain any
known RBE. Specific was distinguished from nonspecific by any protein complex
with the correct location on the 2.66-kb fragment. The same approach to analysis
was used for the 1.7-kb fragment. Since the 953-bp fragment does not contain any
known RBE, all of the Rep complex binding to this fragment was defined as
nonspecific binding. A total of 100 DNA molecules were counted for each
fragment. Binding was reflected as a percentage of the number of DNA mole-
cules that were bound by Rep (Table 1).
Detection of Rep in latently infected cells. HeLa cells which were grown to 80
to 90% confluency on 10-cm plates were infected with a multiplicity of infection
(MOI) of 10 infectious units of wild-type (wt) AAV or with an MOI of 10
infectious units of wt AAV and an Ad type 5 MOI of 20. Mock-infected cells
were also carried to serve as a negative control. Infections were allowed to
proceed for 24 h, and then the supernatant was removed. Cells were rinsed twice
with ice-cold, phosphate-buffered saline (PBS; UNC Tissue Culture Facility).
Cells were then manually scraped and pelleted.
Cell pellets were resuspended in 200 ml of lysis buffer (150 mM NaCl; 50 mM
Tris-HCl, pH 8.0; 5 mM EDTA; 1.0% Triton X-100; 1 mM PMSF). Cells were
incubated on ice for 20 min and then vortexed three times for 10 s each time.
Lysate was transferred to 1.5-ml Eppendorf tubes and spun a 4°C for 10 min at
12,000 rpm to pellet the cellular debris. Cleared lysate was transferred to fresh
Eppendorf tubes, 20 ml of Protein A/G Plus-Agarose beads (Santa Cruz Bio-
technology) was added, and 2 ml of a Rep polyclonal antibody was added.
Reactions were incubated for 2 h at 4°C. After 2 h the reactions were centrifuged
at 2,500 rpm for 5 min. The supernatant was aspirated. Then, 20 ml of 23 sodium
dodecyl sulfate sample buffer (containing a 1:10 dilution of BME) was added.
Pellets were then boiled and loaded onto sodium dodecyl sulfate–10% polyacryl-
amide gel electrophoresis gels. Only half of the immunoprecipitation reaction
was loaded for the Ad-AAV-infected cells. Gels were transferred and immuno-
blotted as previously described (16). Briefly, they were transferred at 500 mA for
20 min using a semidry apparatus (Bio-Rad). The blots were incubated with the
IF11 antibody for 1 h and then incubated with an anti-mouse horseradish per-
oxidase antibody (Amersham) for 1 h. Protein was detected by addition of the
Super Signal Chemiluminescent Substrate (Pierce). Blots were exposed to Bio-
Max MR film (Kodak).
ch-19 amplification detection. Superfect reagent (Qiagen) was used for trans-
fection. Transfections were carried out according to the manufacturer’s protocol.
Cells were grown to 50 to 80% confluency. A total of 10 mg of DNA was used for
transfection. Specifically, 5 mg of pHIV78 (12) and 5 mg of the AAV-Neo
construct with nonfunctional ITRs (pNeo) at a 1:1 ratio were used. DNA was
dissolved in TE (10 mM Tris-HCl, pH 7.5; 0.1 mM EDTA) and diluted into 300
ml of medium lacking serum, proteins, or antibiotics. Next, 40 ml of Superfect
reagent was added to the DNA solution and mixed in by vortexing. Samples were
allowed to incubate for 5 to 10 min at room temperature. While the samples were
incubating, the plates to be transfected were washed with PBS. After incubation,
3 ml of Dulbecco modified Eagle medium (DMEM; Sigma) supplemented with
10% fetal bovine serum (FBS; Sigma) was added to each tube containing the
transfection complexes and then mixed by pipetting. This mixture was then
added to the plates. The cells were incubated with the transfection complexes for
2 h. Fresh medium was added, and cells were maintained for 48 h at 37°C and in
5% CO2 in a tissue culture incubator. Cells were washed four times with 10 ml
of PBS and then diluted to appropriate dilutions for single cell cloning.
G418 selection was carried out on cells that had been transfected with plas-
mids containing the neomycin resistance gene. Cells were placed under 600 mg of
G418 per ml for approximately 8 days. After colonies were picked, cells were
placed in 300 mg of G418 per ml to maintain selection of the neomycin-resistant
cells.
To pick single cell clones, cell were first transfected with the neomycin-resis-
tant gene and then given 48 h to express the resistance gene and to recover from
the transfection. Cells were trypsinized and then plated at densities of 1:10, 1:50,
and 1:100. Cells were placed under G418 selection at 600 mg/ml. After 8 days of
selection, when the colonies had grown to 30 to 50 cells/colony, the cells were
isolated.
To pick the colonies, plates were viewed under low magnification, and colonies
that were well isolated from other colonies were circled on the plate. The
medium was then removed from the plate, and the cells were washed gently with
PBS. Working from the bottom of the plate to the top of the plate, a 10-ml Art
Reach tip filled with 10 ml of trypsin-EDTA (Gibco BRL) was used to scratch
and pull up the colonies of cells. Approximately 10 to 12 colonies were picked,
and then the plate was washed again with PBS to prevent the plate from drying
out. Picked colonies were placed in 96-well tissue culture plates containing,
DMEM with 10% FBS and allowed to grow for approximately 24 to 48 h. After
this the cells were placed under selection with 300 mg of G418 per ml. After cells
had reached confluency, they were passed into dishes with sequentially larger
wells.
RESULTS
Rep filter-binding assay. In order to evaluate the role of
Rep in targeting AAV to ch-19 sequences compared to alter-
native RBE sites, we established a filter-binding assay. The
filter-binding assay was dependent upon a highly purified
source of Rep68 protein that could be easily generated. A
bacterial overexpression system that included an affinity tag
was utilized to achieve this goal. Rep68 protein was cloned into
the pQe70 vector (Qiagen) which fuses a His6 tag to the car-
boxy end. We placed the His6 tag at the carboxy end since
genetic and biochemical characterization had shown that this
portion of the protein can be deleted and still maintain all
known biochemical activities (15, 31, 37). The fusion protein
Rep68H6 is wt in sequence except for a serine-to-alanine
change at amino acid 536, followed by an 8-amino-acid His tag
(RSHHHHHH) after amino acid 537 (Fig. 1A).
Rep68H6 was overexpressed and purified by using a two-
step column purification procedure: Ni-NTA resin (Qiagen),
followed by MonoQ FPLC column (as described in the Mate-
rials and Methods). Silver stain analysis determined that
Rep68H6 had been purified to .95% homogeneity (Fig. 1B),
and immunoblotting confirmed the identity of the purified
material as Rep specific (Fig. 1B). The purified Rep68H6 was
assayed and determined to have all biochemical activities, in-
cluding binding to the AAV ITR and trs endonuclease and
helicase activities as previously described (17) (data not
shown). The yield of purified Rep68H6 was approximately 2 to
5 mg/liter of bacterial culture.
The availability of highly purified Rep protein allowed es-
tablishment of a Rep-dependent filter-binding assay. In es-
sence, digested genomic DNA was incubated with purified
Rep68H6 (Fig. 1C) and passed over a filter under conditions
where only DNA bound to protein was retained. The bound
DNA was subsequently eluted and analyzed by Southern blot.
However, before analyzing Rep68H6 ability to bind specific
sequences within the context of genomic DNA, reaction con-
ditions for specific Rep68H6 binding were established. The
objective was to establish conditions that would bind all po-
tential RBE sequences in the human genome. Using this ap-
proach we determined that 20 pmol of Rep68H6 was the op-
timal amount of protein required to bind as many as 200,000
other potential RBE sites (this is a theoretical number de-













2.7 kb 1:1 40 16 44
1.7 kb 1:1 48.4 11 40.6
953 bp 1:1 0 0 100
a The 2.66-kb ch-19 integration contain an RBE located directly in the center
of the fragment, while the 1.7-kb fragment contains an RBE located 180 nucle-
otides from one end of the fragment; the 953-bp fragment does not contain any
known RBE. “Specific” was distinguished from “nonspecific” as any protein
complex with the correct location on the 2.66-kb fragment. The same approach
to analysis was used for the 1.7-kb fragment. Since the 953-bp fragment does not
contain any known RBE, all Rep complex bound to this fragment was defined as
nonspecific binding. A total of 100 DNA molecules were counted for each
fragment. Binding was reflected as a percentage of the number of DNA mole-
cules that were bound by Rep.
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duced from an 8-bp minimum RBE site; see below) in the
genome (data not shown).
Previous studies demonstrating Rep ability to bind degen-
erate RBE sites (5, 33, 58) strongly suggests that genomic
DNA should compete efficiently in binding assays spiked with
labeled ch-19 target sequences. To test Rep68H6’s ability to
bind the ch-19 target sequence, competition assays were per-
formed in the presence of either genomic or nonspecific com-
petitor DNA [poly(dI-dC)]. As little as 5 mg of genomic DNA
competed away .85% of labeled ch-19 fragment (1 fmol) (Fig.
2A). Maximum amounts of poly(dI-dC) (sixfold higher)
reached only 80% of the level of competition observed with 5
mg of genomic DNA (Fig. 2A). These results demonstrate and
corroborate earlier studies (58) that genomic DNA contains
many potential RBEs, and that these sites can compete for
Rep binding.
In an effort to characterize specificity of the genomic versus
ch-19 Rep interactions, assays were carried out with increasing
amounts of wash buffer. In the absence of Rep, no genomic
DNA was retained on the filter after 10 ml of washing (Fig.
2B). Similar assays carried out in the presence of Rep deter-
mined that 90% of ch-19-specific sequences and 25% of total
genomic DNA was retained even after a 20-ml wash (as deter-
mined by the optical density at 260 nm) (Fig. 2B). We recently
demonstrated that Rep-DNA complexes are sensitive to salt
concentration (data not shown) (62a). We therefore deter-
mined the salt sensitivity of Rep-genomic DNA complexes and
Rep–ch-19 complexes using either unlabeled and labeled sub-
strates, respectively. As the molar amount of KCl was in-
creased, there was a comparable reduction of the amount of
both the ch-19 fragment and genomic DNA retained on the
filter (Fig. 2C). This suggested that the genomic DNA had a
Rep-binding characteristic similar to that of the ch-19 frag-
ment and displayed Rep-binding sensitivity to salt (62a). These
studies support a Rep-dependent interaction with genomic
DNA that is similar to the characterized RBE on ch-19-specific
DNA.
Comparison of Rep68H6 binding preference for RBEs in
genomic DNA. The competition studies carried out above sug-
gested that a portion of genomic DNA could compete for Rep
binding. It was assumed that this interaction was related to
non-ch-19 RBE sequences. To determine the specificity of the
genomic sequences competing in the above reaction, filter-
binding reactions using genomic DNA were analyzed by using
either a ch-19 or a genomic RBE probe identified by a BLAST
search. A previous report using RBE oligonucleotides derived
from GenBank sequences demonstrated positive gel-shifted
complexes when using a Rep68 maltose fusion protein (58). In
one case, an RBE site identified in exon 1 of CSF 1 gene
(CSF1) and identical to ch-19 DNA (58) bound with higher
affinity. Since all 15 RBE oligonucleotides identified by
BLAST analysis bound with higher affinity than a ch-19 oligo-
nucleotide, we tested in the filter-binding assay for the ability
of Rep to the bind ch-19 and CSF1 RBE sites. In this assay, the
high-affinity RBE site of CSF1 was compared to the ch-19
target sequence in the context of digested genomic DNA.
The filter-bound endogenous ch-19 genomic DNA fragment
was visualized after Rep-binding reactions by using Southern
blot analysis. This result allowed us to use this signal as a
reference for positive Rep binding. As an additional control,
genomic DNA was digested with PvuII to separate ch-19 RBE
sequences from ch-19 39-flanking DNA before submitting it to
filter-binding analysis. By hybridizing with 39 ch-19-specific
probes, we could determine Rep binding to non-RBE contain-
ing DNA from the adjacent chromosomal region. PvuII diges-
tion generates a 4.2-kb genomic fragment of ch-19, which does
not contain the ch-19 RBE, and an 898-bp fragment, which
contains the RBE (Fig. 3A). Filter-binding assays were carried
out, and Rep-retained DNA was eluted and fractionated on
agarose gels and probed with a right-half ch-19 sequence-
specific probe (Fig. 3B). Southern analysis demonstrated that
while the 4.2-kb PvuII fragment can be detected in the total
genomic DNA, no signal was observed in the filter-bound lane
even after extended overexposure (data not shown).
Unlike the ch-19 39-flanking sequences, 59 genomic DNA
carrying the ch-19 RBE sequences (BamHI 2.7-kb fragment)
was retained and identified after Southern blot analysis (Fig.
3B). More importantly, CSF1 genomic DNA (BamHI 2.7-kb
fragment) originally identified by BLAST analysis as positive
for an RBE sequence was also retained after Rep filter binding
(Fig. 3D). Filter-bound samples were image quantified after
Southern blot analysis. Approximately 25% of ch-19 genomic
DNA was retained by Rep (Fig. CB, lane 2). In contrast, only
one-third the amount of CSF1 genomic DNA was retained
(Fig. 3D, lane 2). While the number of chromosomes carrying
the CSF sequence are unknown in our aneuploid HeLa cells,
we previously determined that three copies of chromosome 19
are present (46). Based on this information, we calculated a
minimum 2.7-fold difference in Rep affinity for ch-19 se-
quences over CSF1 genomic DNA.
These studies demonstrated that in the context of genomic
DNA both RBE sequences were recognized by Rep and re-
tained. This would imply that all RBE sites in the human
genome compete for Rep binding and that this step is not
sufficient to determine ch-19 site-specific integration. Although
the ch-19 target sequences bound more efficiently (2.7-fold)
than the identical RBE element located in the CSF gene, this
difference was not sufficient enough to explain AAV targeting
frequency. The binding affinity observed was specific since we
saw no retention of the 39 ch-19 genomic DNA devoid of RBE
sequences. In addition, using genomic DNA to compare ch-19
to CSF1 RBE sites, we observed a higher affinity for ch-19 than
that established in an in vitro reaction using oligonucleotides
(58). These results suggest that other ch-19 flanking sequences
within this fragment may influence the recognition of Rep for
the ch-19 RBE site.
Direct visualization of Rep-DNA complexes by EM. Since
Rep binding to the specific ch-19 fragment within genomic
DNA appeared to be more efficient than to the CSF fragment
and since this observation was contrary to published data gen-
erated using 54-bp oligonucleotides, we utilized EM to evalu-
ate whether targeting may be facilitated by other DNA ele-
ments present on ch-19 (i.e., incomplete RBE sequences). To
determine if multiple Rep-binding sites or additional activities,
such as Rep formation of paranemic structures of the target
DNA, occurred after Rep-DNA binding, Rep68H6 and ch-19
DNA were analyzed for size and number of protein-DNA
complexes. A plasmid (pRE2) which contains the ch-19 region
was digested to yield three fragments of 2.7 kb (which contain
the genomic ch-19 sequence with the target RBE element
located in the center), 1.7 kb (which contain a minimal RBE of
59-GAGTGAGC-39 in the plasmid origin and is located ap-
proximately 200 bp away from one end), and 953 bp (devoid of
any RBE sequences). Specific binding versus nonspecific bind-
ing was determined for all three fragments (see Materials and
Methods for details). Rep68H6 was added at protein/DNA
mass ratio of 1:1 (25 monomers of Rep to 1 RBE). The binding
reactions were glutaraldehyde fixed, shadowed with tungsten,
and visualized on EM (Fig. 4). At a mass ratio of 1:1, we found
approximately 50% of the RBE-containing fragments bound to
Rep. Rep complexes were predominantly localized to the cen-
ter of the 2.7-kb fragment (Fig. 4A), asymmetrically localized
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on the 1.7-kb fragment (Fig. 4B), and never localized to the
953-bp fragment, as expected (Fig. 4C) (n 5 100). Rep-DNA
interaction at these ratios did not form gross structural modi-
fications of the target DNAs (i.e., loop structures or intermo-
lecular complexes). The size of the Rep complex bound to
DNA was deemed to be a multimer and spanned an average of
60 bp. This conclusion was based upon comparison to other
known DNA-binding proteins bound to their respective targets
and analyzed by EM, as well as by measuring the area of DNA
covered by the protein complex (data not shown and J. Griffith,
FIG. 2. Optimization of filter-binding reactions. (A) The left panel is a titration of increasing amounts of poly(dI-dC) required to disrupt Rep–ch-19 RBE-specific
binding (as measured by filter binding). The reaction contains 20 pmol of Rep68H6 and 1 fmol of the labeled ch-19 target sequences. The right panel graphs the effect
of increasing amounts of genomic DNA on Rep68H6–ch-19-labeled DNA as measured by the filter binding assay (see Materials and Methods for details). (B) Titration
of nonelution buffer on Rep–ch-19-specific binding by ethidium bromide staining of agarose gel analysis (upper panel) and retention of radio labeled ch-19-specific
probe (lower panel). Lane 1, no Rep68H6 protein; lanes 2 to 6, 0.25, 1.0, 5.0, 10, and 20 ml of nonelution wash buffer, respectively. Lane 7 shows 10 mg of
BamHI-digested HeLa genomic DNA prior to filter binding and elution. In all the reactions, 50 fmol of the 32P-labeled ch-19 fragment from pRE2 was spiked in to
serve as an internal control of Rep-specific binding. Results are graphed in the lower panel. (C) KCl effect on Rep genomic DNA filter-binding assay using ethidium
bromide staining of agarose gel analysis (upper panel) and retention of radio labeled ch-19-specific probe (lower panel). Lane 1, 200 mM KCl; lane 2, 300 mM KCl;
lane 3, 400 mM KCl; lane 4, 500 mM KCl. Reactions were carried out as described in panel A and in Materials and Methods and was followed by washing with 10 ml
of nonelution buffer. The middle part of panel C shows an autoradiogram of retained ch-19 fragment. The lower panel shows a graph of the percentage of the ch-19
fragment retained with respect to increasing amounts of KCl.
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personal communication). These results demonstrate that
there are no other RBEs present on the ch-19 fragment, nor
are there distal sequences (loop structures) stabilizing Rep-
DNA interactions under these Rep concentrations. However,
when Rep-AAV ITR sequences were analyzed using 1:1 ratios,
we routinely observed that 100% of the substrates bound with
the Rep complex to both of the terminal repeats (Fig. 5). In
some of the AAV molecules, we also observed binding to a
position that would correlate to the p5 promoter. The presence
of these complexes and the appearance of DNA looping struc-
tures were observed (data not shown). As previously described,
we saw a higher affinity of Rep for the AAV ITR sequences
under these conditions than for the ch-19 and non-ch-19 RBE
fragments. However, thorough EM analysis (n 5 100) also
demonstrated that there was no preference in Rep binding to
the ch-19 fragment versus the 1.7-kb fragment containing the
minimum 8-bp RBE (Table 1). This result is in contrast to the
results of our Rep genomic filter-binding assay and may reflect
the limited quantitative value of these protocols.
Minimum RBE sites recognized by Rep. By EM analysis, the
8-bp plasmid RBE bound Rep (Table 1) and generated pro-
tein-DNA complexes identical to ch-19 target DNA (Fig. 4).
This result suggests that Rep is unable to discriminate between
the ch-19 target RBE and other non-ch-19 sites. In addition,
these results suggest that there are a multitude of potential
RBEs in the human genome. Competition assays were per-
formed as described in Materials and Methods using a 3.1-kb
lacZ fragment containing a minimal RBE (59-GCGAGCGA-
39), the 2.7-kb cloned BamHI fragment RBE (59-GAGCGAG
CGAGC-39) from the ch-19 integration site, and a cloned
CSF1 RBE (59-GAGCGAGCGAGCGAGC-39) cDNA frag-
ment (938 bp). Inclusion of a 2.1-kb fragment devoid of any
RBE sequences was used as a negative control. Under these
conditions, the three fragments with RBE sequences competed
against labeled ch-19–Rep DNA to the same degree (Fig. 6).
Nonspecific DNA did not show competition below a 100-fold
molar excess, suggesting that the fragments containing non-
ch-19 RBE sites were effective at binding Rep.
These competition results support the EM analysis and sug-
gest that Rep68H6 is unable to discriminate between ch-19 and
non-ch-19 RBE sites in the human genome. From all of these
observations, our data support the idea that AAV Rep is bind-
ing to non-ch-19 RBE sequences in the human genome. If we
utilize the in vitro binding results to the 8-bp RBE as a mini-
mum viable site, then potentially 2 3 105 RBE sites exist per
genome. This observation suggests that the amount of Rep
expressed during a latent infection could be rate limiting for
AAV targeted integration.
Detection of Rep in a latent infection. With approximately
2 3 105 RBE/genome, this raises the critical question as to how
Rep can localize to the AAV ITR and the ch-19 target se-
quence for site-specific integration among numerous similar
FIG. 3. Southern Blot analysis of filter-bound genomic DNA. (A) Diagram of the 2.7-kb ch-19 integration region. The RBE-trs is labeled and shown as a black box,
while the sequence recognition region of the probe used for all analysis is depicted as a solid line. The distance between the two PvuII sites is 898 bp. (B) Filter-binding
assay of ch-19 sequences devoid of any known RBE sequences. Genomic DNA digested with PvuII (one site in the 2.7-kb fragment and the other 39 to the BamHI site)
is specific for a 4-kb ch-19 fragment devoid of RBE sequences. Lane 1, signal generated with 10 mg of PvuII-digested HeLa genomic DNA prior to filter binding assay;
lane 2, signal generated after loading DNA eluted from one filter-binding reaction. Hybridization was carried out with the PvuII-BamHI right-side-specific probe (see
panel A). (C) Southern analysis demonstrating Rep68H6’s ability to retain ch-19 sequences carrying RBE sequences after the filter-binding assay. Lane 1, signal
generated from 10 mg of BamHI-digested HeLa genomic DNA prior to filter binding; lane 2, signal generated from four pooled filter-binding reactions; lane 3, signal
generated from one filter-binding reaction. The arrow indicates the position of the ch-19 fragment (pRE2). (D) Rep68H6 retention of non-ch-19 RBE genomic
sequences. Lane 1, signal generated from 10 mg of BamHI-digested HeLa genomic DNA prior to filter-binding reaction; lane 2, signal generated from four pooled
filter-binding reactions; lane 3, signal generated from one filter-binding reaction. The blot was probed with a SmaI-PstI fragment from pcCSF17, which recognizes exon
1 from the CSF1 gene (see Materials and Methods for details). The arrow indicates the position of the CSF1 fragment.
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binding sites. Under this scenario, the amount of Rep ex-
pressed in a nonlytic infection becomes essential to its ability to
carry out site-specific integration in the context of numerous
RBE sequences. To determine the amount of Rep expressed in
productive versus nonproductive infection, immunoprecipita-
tion-Western analysis on 107 HeLa cells infected with Ad plus
AAV or with AAV alone (MOI 5 10), was carried out as
described in Materials and Methods. Analysis of the Ad-AAV
infection extract revealed that all four Rep proteins were pro-
duced in significant amounts (Fig. 7), as expected (3). In con-
trast to the Ad-AAV infection, only a faint band that corre-
sponded to Rep52 was detected in the AAV-infected cells
under similar exposures. Rep68 and Rep78 were detected in
the AAV only infection after a 60-fold overexposure of the blot
(Fig. 7). At this exposure, no protein in the mock-infected lane
was detected, except for the rabbit immunoglobulin G that
cross-reacted with the secondary antibody (Fig. 6). Using a
serial dilution of purified Rep as a standard, the sensitivity of
this assay was determined to be 200 pg (data not shown). Based
on 107 cells, this value corresponds to a limit of detection of
approximately 200 molecules of Rep78 or Rep68 per cell.
After image quantification, we calculated approximately 1,000
to 4,000 Rep78 and Rep68 molecules per latent infected cell.
In addition to 1 to 4,000 molecules of Rep78 and Rep68,
Rep52 (3,000 to 6,000 molecules) but not Rep40 was detected
under these conditions.
AAV Rep induces ch-19 amplification. Most DNA-binding
proteins associate with their specific sites at a rate that can
exceed 109 M21 s21 (55). If we make a similar analogy to AAV
Rep (using 200,000 sites per cell), this result suggests that there
are sufficient Rep molecules available to interact with all po-
tential RBEs within the human genome in a matter of minutes.
Therefore, the Rep ability to target ch-19 must be related to
subsequent steps after DNA binding. Previously, Linden et al.
(30) determined that, in addition to the ch-19 RBE sequence,
the targeting frequency was dependent on the presence of a trs
site. This would imply that after Rep binds to a RBE site, the
presence of a trs site is critical to targeting. To determine if
Rep protein in HeLa cells influenced the ch-19 target sequence
in the absence of ch-19 ITR targeting substrates, we cotrans-
fected cells with Rep expressing plasmids and constructs car-
rying the neomycin resistance gene and isolated neomycin-
specific clones. As shown in Fig. 8, we observed amplification
and rearrangement of the ch-19-specific target DNA (Fig. 8,
lanes 1, 2, and 3) in all cells that received Rep-expressing
plasmids. Although we did not observe any targeted integra-
FIG. 4. EM analysis of Rep-DNA complexes at protein/DNA mass ratios of 1:1. (A) Rep68H6 protein bound to the center RBE of the 2.7-kb ch-19 integration
fragment. (B) Rep68H6 protein bound to the asymmetric RBE of the 1.7-kb DNA fragment. (C) A 953-bp DNA fragment devoid of any RBE sequence and to which
Rep68H6 did not bind. Protein binding and EM processing were carried out as described in Materials and Methods. Bar, 0.5 kb.
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tion of the Neo plasmids into these cells (data not shown),
these DNA rearrangements were similar to those described for
targeted wt AAV integration. We never observed ch-19 ampli-
fication or rearrangement in cells that did not obtain Rep-
expressing plasmids (data not shown). This observation sup-
ports in vitro studies demonstrating Rep-dependent
replication of ch-19 sequences and suggests that even in the
absence of functional AAV cis-acting targeting sequences,
trans-acting Rep protein will act on the ch-19 integration locus.
Rep-dependent targeting to the mouse X chromosome. The
above experiments support a role for Rep in AAV targeted
integration by discriminating between ch-19 and non-ch-19
RBE sites through the presence of a trs sequence. In the
presence of a trs site, Rep-induced DNA replication ensues
potentially providing a substrate for targeted integration. The
ch-19 RBE (8 bp), including the spacing and sequence of the
trs (5 bp), most likely constitute a unique target sequence (15
bp) in the human genome, thereby ensuring AAV integration
specificity. To test this hypothesis, we generated “knockin”
mice that carried a portion of the ch-19 sequence on the mouse
X chromosome (R. J. Samulski et al., manuscript submitted).
Previously, we determined that the AAV target sequence was
only conserved in human and nonhuman primates (R. J. Sam-
ulski, unpublished data), thereby providing a unique opportu-
nity to study AAV targeted integration in this model. Primary
mouse fibroblast cells were isolated from ch-19 mice and in-
fected with AAV-Neo vectors carrying Rep coding sequences.
Genomic DNA was digested with a no-cut enzyme for the
vector sequence or the human ch-19 sequences and subjected
to fractionation on agarose gel and characterized for targeted
integration by Southern analysis by using ch-19 and neomycin
sequence-specific probes (Fig. 9). Using this assay, we deter-
mined the colocalization of the AAV Neo sequences with the
human ch-19 sequences located on the mouse X chromosome.
PCR junction analysis (data not shown) and filter-binding re-
actions confirmed the targeted integration of the AAV genome
to this new chromosome location. These studies support the
observations of Linden et al. (30) and Rizzuto et al. (40), which
identified that ch-19 cis sequences are required for targeted
integration when using an EBV shuttle vector in human cells
or when integrated in the mouse and rat genome. In addition,
these findings suggest that host enzymes required for AAV
targeted integration are conserved in human and rodents and
provide a mouse model for studying AAV site-specific integra-
tion.
DISCUSSION
In this study, we developed a Rep-dependent filter binding
assay to evaluate the role of cellular RBE sites in AAV tar-
geted integration. Using a highly purified source of Rep pro-
tein, we determined that human total genomic DNA can ef-
fectively compete for Rep binding. Southern analysis of
genomic DNA before and after Rep-dependent filter binding
demonstrated the specific retention of the ch-19 integration
locus fragment containing the RBE and trs sequence, as well as
non-ch-19 cellular DNA carrying only an RBE sequence.
These results support the study by Wonderling et al. that iden-
tified alternative RBE sites existing in the human genome by
BLAST analysis (58). Although we observed higher affinity for
FIG. 5. EM analysis of Rep-DNA complexes at a protein/DNA mass ratio of 1:1. The DNA substrate was an AAV no-end viral sequence. Analysis was carried out
as described in the text. All molecules displayed uniform Rep protein complexes associated with the terminal sequences (two examples are provided). Bar, 1 kb.
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ch-19 RBE sequences (2.7-fold) than for heterologous DNA
carrying identical elements using this assay, this difference ap-
pears to be insufficient to explain AAV targeting. In fact, using
these experimental conditions, we did not identify any features
that would make the ch-19 locus a preferred site for Rep
binding. For example, EM analysis of Rep-DNA complexes
demonstrated highly uniform multimeric complexes on both
ch-19 and non-ch-19 RBE sequences. These protein structures
FIG. 6. Competition assay for Rep binding using different RBE DNA sub-
strates. Filter-binding assays were assayed using 4 fmol of labeled BamHI ch-19
fragment from plasmid pRE2 in a 50-ml reaction volume. Rep68H6 and genomic
DNA concentrations were the same as in the original assay conditions (see
Materials and Methods). Increasing molar amounts of 3.1-kb lacZ fragment (‚),
2.7-kb BamHI ch-19 fragment (E), 938-bp CSF1 fragment (h), and 2.1-kb
nonspecific linearized pT7-7 BT plasmid ({) were added to each reaction.
Filter-binding reactions were carried out in a 96-well dot blot apparatus and
washed with 2 ml of nonelution wash buffer before quantitation. Filters were
then exposed to the phosphorimager cassette and the relative intensity was
measured. Respective labeled dots were then cut and quantitated using a scin-
tillation counter to corroborate the phosphorimager analysis. The data were then
plotted as a function of fraction bound versus molar amount of competitor.
FIG. 7. Immunoprecipitation-Western analysis of Rep expression in AAV-infected cells. HeLa cells were infected with AAV alone or Ad-AAV, and protein extracts
were isolated and assayed for Rep expression using AAV Rep-specific antibody. Lanes 1, 2, 4, and 5 show Western blot analysis of AAV Rep expression from 107 HeLa
cells either mock infected (lanes 1 and 4) or AAV infected (lanes 2 and 5) that were exposed for 1 min (lanes 1 and 2) or 1 h (lanes 4 and 5). Lane 3 was a positive
control of 5 3 106 Ad-AAV-coinfected HeLa cells demonstrating expression of all forms (78, 68, 52, and 40 kDa) of the AAV Rep proteins.
FIG. 8. Southern blot analysis of the amplified ch-19 region. HeLa cells were
cotransfected with a Rep expression plasmid and Neo construct. Cells were G418
selected, and single colonies were picked and grown up. DNA from individual
cell lines was digested with a restriction endonuclease that does not cut within
the ch-19 region and was probed with a ch-19-specific probe. Control, untreated
HeLa cells; lanes 1 to 3, cell lines derived after transfection with Rep expression
plasmids.
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covered about 60 bp of DNA and appeared to be indistinguish-
able for ch-19, non-ch-19, and AAV ITR RBE sites. We never
observed Rep binding to control DNA substrates lacking the
RBE site. In fact, under these conditions we were able to
establish Rep-binding complexes with minimum RBE ele-
ments of 8 bp, suggesting that as many as 200,000 Rep-binding
sites may exist in the human genome. These results imply that
Rep may interact with numerous RBE sites distributed across
the human genome as part of the integration mechanism.
Rep levels in a latent infection. Based on this result, the
amount of Rep in a latent infection could be considered as a
rate-limiting step for AAV site-specific integration. For this
reason, we determined the amount of Rep expressed in the
first 24 h of a nonlytic infection. Our analysis suggested that 1
to 4,000 copies of Rep78 and Rep68 are available for facilitat-
ing targeted integration. At present, the rate association con-
stant for Rep and cellular RBE sites have not been deter-
mined. Other DNA-binding proteins (e.g., Drosophila
doublesex and Lambda Cro) typically have rate association
constants on the order of 106 (6) and 108 (22), respectively.
Extrapolating from other known DNA association constants
and the time observed for AAV integration (24 h) (34), this
would suggest that the level of Rep78 and Rep68 present in a
nonproductive infection (1 to 4,000 molecules) should be suf-
ficient to interact with all 200,000 potential RBE sites. While it
is tempting to suggest this argument, determination of Rep-
RBE association constants need to be established before firm
conclusions can be made. However, even if Rep is inefficient at
binding, it is important to note that, in vivo, it is unlikely that
all 200,000 sites are accessible to Rep binding due to their
chromatin structure. In fact, a recent study has shown that the
ch-19 site is DNase hypersensitive (27), implying a chromatin
structure that is accessible for protein interactions. This obser-
vation implies that ch-19 is always available for Rep interac-
tion, whereas other sites may be subject to local chromatin
environment during the cell cycle. These factors strengthen the
notion that 1,000 to 4,000 molecules of Rep could be sufficient
for targeting the viral genome in the absence of any other
features.
Rep protein complexes. Our characterization of purified
Rep-DNA complexes by EM analysis represents the first visual
identification of a multimeric-protein complex interacting with
the Rep binding site. The fact that Rep complexes were mul-
timeric is not surprising since it has been reported that Rep
forms multiple protein-DNA complexes (33) and may poten-
tially bind as a hexamer (48). The observation that Rep can
span a region of DNA of about 60 bp, however, does provide
an explanation as to why Rep does not bind efficiently to small
oligonucleotides as described by Chiorini et al. (4). It is possi-
ble that the RBE DNA induces multimerization of the Rep68
protein since the Rep protein concentration used in the EM
experiments (16 nM) was significantly lower than that for Rep
when it exists as a monomer in solution (380 nM or 25 ng/ml).
It is interesting to note that previous studies have suggested
Rep-Rep interactions when there is binding to the DNA RBE
motif (32, 33). Our observations clearly establish that Rep
complexes interacting with either AAV ITR, ch-19 RBE, or
minimum RBE element derived from plasmid DNA form
identical protein structures (Fig. 4). It was interesting to note
that, given that the 953-bp fragment with no RBE showed no
nonspecific binding, the RBE-containing units had 11 and 15%
nonspecific binding (Table 1). This observation suggests that
the presence of a strong RBE increases the local concentration
of Rep enough to allow interaction with low-affinity sites on
the same DNA strand. This may be a factor that is important
in vivo, where competition for Rep (RBE sites) and the initi-
ation for site-specific recombination may be influenced by the
local concentration of Rep molecules (Rep-Rep interactions).
However, further experiments are required to evaluate this
hypothesis.
Regardless, as previously indicated by gel shift assays, EM
analysis also revealed a higher affinity of Rep for the ITR (Fig.
5) when it was compared to either ch-19 or analogous RBE
sequences (Table 1). Based on this observation we hypothesize
that Rep levels in a newly infected cell will allow constant
occupation of the AAV ITR sequences compared to transient
binding to cellular RBE elements other than ch-19. This would
imply that a preformed AAV ITR-Rep complex is a separate
substrate that may interact with chromosomal RBE sites or
chromosomal Rep-RBE complexes. If the ITR-Rep complex
interacts with a Rep-chromosome complex as a separate entity,
then the formation of the appropriate Rep-chromosome RBE
complex would become the rate-limiting determinant for tar-
geted recombination.
Cellular factors. It is important to take into account that all
of our binding analyses were performed with purified Rep
only. Recent evidence has demonstrated a role for high-mo-
bility group (HMG) proteins in NS1 nicking of the MVM
genome (8). This protein has also enhanced Rep binding and
nicking activity on the AAV ITR (7) and has enhanced in vitro
targeting of AAV substrates (9). HMG proteins have been
implicated in bending DNA and making it more flexible (36,
38, 39). Therefore, our observations with purified Rep would
likely be enhanced in the presence of HMG. Cellular proteins
could clearly impact the efficiency of Rep-mediated integration
(62), and this fact points to a limitation of our study design.
The in vitro observations we have described, however, were
extended by using normal diploid cells derived from a ch-19
mouse (see below).
Rep-dependent ch-19 replication. Our experiments that as-
sayed for Rep effect on ch-19 yielded interesting observations
FIG. 9. Comigration of ch-19 target sequences from primary mouse cells with
Rep-Neo vector DNA after analysis by the Southern blot technique. Primary
mouse embryo fibroblast (PMEF) cells were infected with a recombinant Rep-
Neo AAV virus. Latent cells which were Neo resistant were established as
described in Materials and Methods. Lane 1, 10 mg of XbaI-digested ch-19
(PMEF) DNA fractionated on agarose gel, transferred to membrane, and hy-
bridized with a ch-19 sequence-specific probe; lane 2, 10 mg of XbaI-digested
ch-19 PMEF DNA was fractionated on agarose, transferred by Southern blot-
ting, and hybridized with a Neo sequence-specific probe.
VOL. 74, 2000 AAV Rep PROTEIN IN SITE-SPECIFIC RECOMBINATION 3963
with regard to AAV targeted integration. The ability to amplify
ch-19 in the absence of viral integration substrates strongly
suggest that Rep-mediated replication is a primary step for
AAV targeting. These observations support earlier studies by
Urcelay et al. (54) that described an in vitro Rep-dependent
replication of ch-19 DNA carrying the RBE-trs site. From
these observations, it appears that a critical step in the AAV
integration process involves Rep-dependent nicking of the
ch-19 substrate. Our studies also demonstrate cellular ampli-
fication in the absence of viral targeting sequences, suggesting
that Rep initiates a replication event on ch-19 that results in
amplification and rearrangement. This amplification and rear-
rangement may result from Rep-dependent unscheduled initi-
ation of ch-19 replication. These observations also suggest the
possibility that the head-to-tail configuration of viral integrants
appears as a by-product of this replication event. It is interest-
ing to note that proviral structures for AAV vectors devoid of
Rep result in identical head-to-tail concatemers, albeit at ran-
dom sites in the genome (25, 34, 62). In addition, recent anal-
ysis of simian virus 40 integration has documented identical
head-to-tail proviral structures, implying that this may be a
universal cellular mechanism for “amplified” integration (52).
These data imply that host machinery is responsible for the
head-to-tail amplification and that the role of Rep is to direct
the recombination event through initiation of replication on a
virus-like origin (RBE-trs) located on ch-19. These observa-
tions also provide an explanation as to why latent proviral
structures (head to tail) generated by host enzymes do not
resemble the Rep-dependent viral replication intermediates
(head to head) seen in a lytic infection. In addition, EM data
suggest that the Rep complex may be associated with the viral
TR sequences prior to initiating replication on ch-19. It is still
undetermined whether the viral Rep-TR complex requires
nicking in order to recombine with the ch-19 target sequence.
While rescue of proviral AAV genomes requires functional
terminal repeats for replication and packaging, the precise role
in integration is still undefined. These data suggest that if Rep
independently forms a complex on ch-19 and initiates replica-
tion, this may be a hot spot for Rep-Rep DNA complexes to
assemble, in a manner similar to that of the punctate replica-
tion centers described by Hunter et al. (16), for wt AAV lytic
infection.
Animal model for AAV targeting. In vivo characterization of
Rep-dependent replication of ch-19 suggests that AAV tar-
geted integration is dependent on a replication and not on a
viral integrase-like mechanism for targeted integration. More
importantly, these observations, coupled with earlier studies
identifying the ch-19 minimum cis sequences, suggest that
AAV targeted integration can be characterized both in vitro
and in vivo. This may be important in determining the targeted
integration potential of different cell types. In an effort to
generate an animal model suitable for AAV targeted integra-
tion, we utilized a cis sequence (2.7 kb) from ch-19 to generate
a knockin transgenic mouse (Samulski et al., submitted). This
animal now carries the targeting sequences on the X chromo-
some located in the HPRT site. Our initial characterization
using Rep-Neo vectors demonstrated targeted integration into
the ch-19 sequences now located on the mouse X chromosome.
These observations confirm two points: (i) host enzymes in-
volved in AAV targeted integration are conserved between
rodents and humans, and (ii) the targeting locus carries the
sequence information (e.g., chromatin structure) required to
identify this region for recombination. This premise is sup-
ported by the fact that Lamartina et al. determined that this
sequences carries a DNase hypersensitive site which may fa-
cilitate the targeting process (27). Recently, Rizzuto et al. (40)
established a rat model carrying a different but overlapping
portion of ch-19 for targeting. From these two experimental
animal models, a minimum sequence of 1.6 kb was found to be
common, suggesting that this sequence may be sufficient for
targeting in vivo. Prior to these studies, Linden et al. (29, 30)
established by using an integration assay dependent on an
EBV episome carrying the ch-19 sequence that a minimum of
33 bp was sufficient for targeting. Previously, a sequence 59 to
the RBE was determined to cause instability in the EBV sys-
tem. This is the same region identified by Lamartina et al. for
DNase hypersensitivity. It is interesting to speculate that these
sequences (which are not required in the episomal system) may
be required for targeting to the chromosomal locus. It remains
to be determined if the 33-bp sequence alone will retain tar-
geting in a chromosomal locus. Regardless, the studies involv-
ing these animals strongly support the idea that this region of
human ch-19 containing the RBE-trs sequences is unique in
the human and simian genome and will function when moved
to a new location. This animal model should be useful now for
studying AAV integration in vivo in diploid cells. More impor-
tantly, this model may provide a research tool for studying
chromosomal targeting using AAV plasmid vectors.
At present, 1% of AAV infecting viral genomes integrate
with approximately 70 to 90% of these proviruses targeted to
ch-19 (35). Though this is an efficient reaction for targeting, the
overall integration frequency is marginal at best. We can iden-
tify at least five successive steps that would impact AAV tar-
geted integration after infection: (i) after successful viral entry
and uncoating, the conversion of single-stranded to double-
stranded DNA, providing a template competent for mRNA
expression; (ii) expression of Rep proteins; (iii) Rep interac-
tion and complex formation with viral ITR and/or chromo-
somal RBEs; (iv) Rep-dependent replication of the ch-19 lo-
cus; and (v) Rep-ITR complexes interacting with Rep–ch-19
replicated substrates, facilitating targeted recombination and
resulting in head-to-tail proviral structures via host enzymes.
In conclusion, we have utilized a highly purified source of
Rep to investigate the role of this protein in AAV targeted
integration. It is apparent that Rep can interact with numerous
RBE like sequences in the human genome (ca. .105 sites) and
that the differential affinity of Rep for these sites is unlikely to
provide the specificity of targeted integration. EM studies sug-
gest that large multimeric Rep protein complex binds to de-
generate RBE sites as well as to the ch-19 site. Rep initiates
replications at the ch-19 target locus in the presence or absence
of a viral genome. This event leads to amplification of ch-19
that may continue after recombination of the viral genome to
generate concatemeric proviral structures. Finally, these re-
combination products can be generated at both endogenous
ch-19 position, as well as at heterologous sites generated in a
mouse model. Further analysis of these observations should
provide a molecular understanding for the role of Rep in AAV
site-specific recombination in vivo.
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